Hoffmann-La Roche

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

1. Trial

   PHASE3 registered

   Sep 1, 2026

   Non-small Cell Lung Cancer · NOT_YET_RECRUITING · sponsor: Hoffmann-La Roche · A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

   ClinicalTrials.gov · NCT07541170 (opens the source filing in a new tab)

2. Trial

   PHASE2 registered

   Aug 1, 2026

   Relapsing-remitting Multiple Sclerosis · NOT_YET_RECRUITING · sponsor: Hoffmann-La Roche · A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

   ClinicalTrials.gov · NCT07503340 (opens the source filing in a new tab)

3. Trial

   PHASE3 registered

   Jun 30, 2026

   Multiple Myeloma · RECRUITING · sponsor: Hoffmann-La Roche · Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

   ClinicalTrials.gov · NCT07555938 (opens the source filing in a new tab)

4. Trial

   PHASE2 registered

   Apr 7, 2026

   Breast Cancer · RECRUITING · sponsor: Hoffmann-La Roche · A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

   ClinicalTrials.gov · NCT07405801 (opens the source filing in a new tab)

5. Trial

   PHASE1 registered

   Mar 31, 2026

   Stable Coronary Artery Disease, Healthy Volunteers · RECRUITING · sponsor: Hoffmann-La Roche · A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease

   ClinicalTrials.gov · NCT07495813 (opens the source filing in a new tab)

6. Trial

   PHASE2 registered

   Mar 16, 2026

   Antiphospholipid Syndrome · WITHDRAWN · sponsor: Hoffmann-La Roche · A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS)

   ClinicalTrials.gov · NCT07172022 (opens the source filing in a new tab)

7. Trial

   Study registered

   Feb 23, 2026

   Early-stage HER2+ Breast Cancer · RECRUITING · sponsor: Hoffmann-La Roche · A Study to Assess Treatment Patterns and Treatment Adherence in Early HER2-positive Breast Cancer Participants After Treatment Decentralization

   ClinicalTrials.gov · NCT07527741 (opens the source filing in a new tab)

8. Trial

   PHASE2 registered

   Feb 18, 2026

   Breast Cancer · RECRUITING · sponsor: Hoffmann-La Roche · To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

   ClinicalTrials.gov · NCT07368998 (opens the source filing in a new tab)

9. Trial

   Study registered

   Feb 9, 2026

   Traumatic Brain Injury · RECRUITING · sponsor: Hoffmann-La Roche · A Study to Develop a Blood-based Test for Aiding the Diagnosis/Prognosis of Traumatic Brain Injury in Adults and for Monitoring the Development of Secondary Events in Patients Diagnosed With Traumatic Brain Injury

   ClinicalTrials.gov · NCT07455136 (opens the source filing in a new tab)

10. Trial

    PHASE2 registered

    Feb 1, 2026

    Colorectal Cancer · WITHDRAWN · sponsor: Hoffmann-La Roche · A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer

    ClinicalTrials.gov · NCT07323576 (opens the source filing in a new tab)

11. Trial

    PHASE1 registered

    Dec 22, 2025

    Healthy Volunteers · RECRUITING · sponsor: Hoffmann-La Roche · A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7806881 in Healthy Participants

    ClinicalTrials.gov · NCT07271693 (opens the source filing in a new tab)

12. Trial

    PHASE1 registered

    Nov 19, 2025

    Huntington's Disease · RECRUITING · sponsor: Hoffmann-La Roche · A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease

    ClinicalTrials.gov · NCT07246941 (opens the source filing in a new tab)

13. Trial

    PHASE3 registered

    Oct 24, 2025

    Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer · RECRUITING · sponsor: Hoffmann-La Roche · A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

    ClinicalTrials.gov · NCT06793215 (opens the source filing in a new tab)

14. Trial

    Study registered

    Sep 29, 2025

    Diffuse Large B-Cell Lymphoma · RECRUITING · sponsor: Hoffmann-La Roche · An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma

    ClinicalTrials.gov · NCT07200375 (opens the source filing in a new tab)

15. Trial

    PHASE3 registered

    Sep 17, 2025

    Alzheimers Disease · RECRUITING · sponsor: Hoffmann-La Roche · A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

    ClinicalTrials.gov · NCT07169578 (opens the source filing in a new tab)

16. Trial

    PHASE4 registered

    Jul 9, 2025

    Dry Eye Disease · ACTIVE_NOT_RECRUITING · sponsor: Hoffmann-La Roche · A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment

    ClinicalTrials.gov · NCT07025811 (opens the source filing in a new tab)

17. Trial

    PHASE4 registered

    Jul 4, 2025

    Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis · ACTIVE_NOT_RECRUITING · sponsor: Hoffmann-La Roche · A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

    ClinicalTrials.gov · NCT07483450 (opens the source filing in a new tab)

18. Trial

    PHASE3 registered

    Jul 2, 2025

    Alzheimers Disease · RECRUITING · sponsor: Hoffmann-La Roche · Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

    ClinicalTrials.gov · NCT07177352 (opens the source filing in a new tab)

19. Trial

    PHASE3 registered

    Apr 9, 2025

    Breast Cancer · RECRUITING · sponsor: Hoffmann-La Roche · A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

    ClinicalTrials.gov · NCT06790693 (opens the source filing in a new tab)

20. Trial

    Study registered

    Dec 30, 2024

    Bacterial Vaginosis, Candida Vaginitis · COMPLETED · sponsor: Hoffmann-La Roche · Performance Study of the Cobas® BV/CV Test on Samples From Participants With and Without Symptoms of Bacterial Vaginosis and Candida Vaginitis

    ClinicalTrials.gov · NCT06975436 (opens the source filing in a new tab)

21. Trial

    PHASE3 registered

    Dec 13, 2024

    Multiple Sclerosis · RECRUITING · sponsor: Hoffmann-La Roche · An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment

    ClinicalTrials.gov · NCT06675955 (opens the source filing in a new tab)

22. Trial

    PHASE1/PHASE2 registered

    Nov 18, 2024

    Non-Small Cell Lung Cancer · ACTIVE_NOT_RECRUITING · sponsor: Hoffmann-La Roche · A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)

    ClinicalTrials.gov · NCT06624059 (opens the source filing in a new tab)

23. Trial

    Study registered

    Oct 21, 2024

    Relapsing Remitting Multiple Sclerosis · RECRUITING · sponsor: Hoffmann-La Roche · Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis

    ClinicalTrials.gov · NCT05949580 (opens the source filing in a new tab)

24. Trial

    PHASE3 registered

    Jun 17, 2024

    Neovascular Age-related Macular Degeneration, nAMD · RECRUITING · sponsor: Hoffmann-La Roche · A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)

    ClinicalTrials.gov · NCT05562947 (opens the source filing in a new tab)

25. Trial

    Study registered

    May 9, 2024

    Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion · ACTIVE_NOT_RECRUITING · sponsor: Hoffmann-La Roche · Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)

    ClinicalTrials.gov · NCT06439576 (opens the source filing in a new tab)

26. Trial

    PHASE1 registered

    Dec 18, 2023

    Systemic Lupus Erythematosus · ACTIVE_NOT_RECRUITING · sponsor: Hoffmann-La Roche · A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus

    ClinicalTrials.gov · NCT05835986 (opens the source filing in a new tab)

27. Trial

    PHASE1/PHASE2 registered

    Dec 12, 2023

    Relapsed or Refractory Multiple Myeloma · COMPLETED · sponsor: Hoffmann-La Roche · A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

    ClinicalTrials.gov · NCT06055075 (opens the source filing in a new tab)

28. Trial

    PHASE3 registered

    Dec 11, 2023

    Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer · RECRUITING · sponsor: Hoffmann-La Roche · A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

    ClinicalTrials.gov · NCT06065748 (opens the source filing in a new tab)

29. Trial

    PHASE1 registered

    Dec 11, 2023

    PIK3CA-Mutated Cancers · ACTIVE_NOT_RECRUITING · sponsor: Hoffmann-La Roche · A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers

    ClinicalTrials.gov · NCT06496568 (opens the source filing in a new tab)

30. Trial

    NA registered

    Sep 14, 2023

    Metastatic Lung Cancer, Metastatic Gastrointestinal Cancer · COMPLETED · sponsor: Hoffmann-La Roche · A Study to Evaluate the Impact of Liquid Biopsy in Participants With a Clinical Diagnosis of Advanced Cancer

    ClinicalTrials.gov · NCT05846594 (opens the source filing in a new tab)

31. Trial

    Study registered

    Aug 11, 2023

    Carcinoma, Non-Small-Cell Lung · ACTIVE_NOT_RECRUITING · sponsor: Hoffmann-La Roche · A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be Treated With Surgery

    ClinicalTrials.gov · NCT05872763 (opens the source filing in a new tab)

32. Trial

    PHASE3 registered

    Aug 8, 2023

    Primary IgA Nephropathy · RECRUITING · sponsor: Hoffmann-La Roche · A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

    ClinicalTrials.gov · NCT05797610 (opens the source filing in a new tab)

33. Trial

    PHASE2 registered

    May 4, 2023

    PD-L1-selected Solid Tumors · COMPLETED · sponsor: Hoffmann-La Roche · A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors

    ClinicalTrials.gov · NCT05661578 (opens the source filing in a new tab)

34. Trial

    PHASE3 registered

    Jan 9, 2023

    Uveitic Macular Edema · COMPLETED · sponsor: Hoffmann-La Roche · A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema

    ClinicalTrials.gov · NCT05642312 (opens the source filing in a new tab)

35. Trial

    PHASE1 registered

    Nov 4, 2022

    Diffuse Large B-Cell Lymphoma (DLBCL) · COMPLETED · sponsor: Hoffmann-La Roche · A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma

    ClinicalTrials.gov · NCT05364424 (opens the source filing in a new tab)

36. Trial

    PHASE2 registered

    Aug 15, 2022

    Melanoma · COMPLETED · sponsor: Hoffmann-La Roche · A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma

    ClinicalTrials.gov · NCT05419388 (opens the source filing in a new tab)

37. Trial

    PHASE4 registered

    Aug 2, 2022

    Neuromyelitis Optica Spectrum Disorder, NMOSD · TERMINATED · sponsor: Hoffmann-La Roche · A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention

    ClinicalTrials.gov · NCT05269667 (opens the source filing in a new tab)

38. Trial

    PHASE2 registered

    Jul 22, 2022

    Solid Tumors · COMPLETED · sponsor: Hoffmann-La Roche · Screening Study for Participants With Malignant Tumors

    ClinicalTrials.gov · NCT05419375 (opens the source filing in a new tab)

39. Trial

    PHASE4 registered

    Apr 13, 2022

    Multiple Sclerosis, Clinically Isolated Syndrome · COMPLETED · sponsor: Hoffmann-La Roche · A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy

    ClinicalTrials.gov · NCT04998812 (opens the source filing in a new tab)

40. Trial

    PHASE1 registered

    Aug 11, 2021

    Multiple Sclerosis · RECRUITING · sponsor: Hoffmann-La Roche · A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis

    ClinicalTrials.gov · NCT05704361 (opens the source filing in a new tab)

41. Trial

    PHASE3 registered

    Jul 14, 2021

    Neovascular Age-related Macular Degeneration (nAMD) · ACTIVE_NOT_RECRUITING · sponsor: Hoffmann-La Roche · A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

    ClinicalTrials.gov · NCT04657289 (opens the source filing in a new tab)

42. Trial

    PHASE1 registered

    Jul 14, 2021

    Metastatic Colorectal Cancer · COMPLETED · sponsor: Hoffmann-La Roche · Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment

    ClinicalTrials.gov · NCT04826003 (opens the source filing in a new tab)

43. Trial

    PHASE1/PHASE2 registered

    Jun 22, 2021

    Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer · RECRUITING · sponsor: Hoffmann-La Roche · A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

    ClinicalTrials.gov · NCT04802759 (opens the source filing in a new tab)

44. Trial

    PHASE2 registered

    Jan 18, 2021

    Solid Tumors · ACTIVE_NOT_RECRUITING · sponsor: Hoffmann-La Roche · Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

    ClinicalTrials.gov · NCT04589845 (opens the source filing in a new tab)

45. Trial

    PHASE3 registered

    Dec 3, 2020

    Multiple Sclerosis · ACTIVE_NOT_RECRUITING · sponsor: Hoffmann-La Roche · A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

    ClinicalTrials.gov · NCT04548999 (opens the source filing in a new tab)

46. Trial

    PHASE1/PHASE2 registered

    Sep 3, 2020

    Advanced Solid Tumors, HER2-positive Breast Cancer · ACTIVE_NOT_RECRUITING · sponsor: Hoffmann-La Roche · A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

    ClinicalTrials.gov · NCT05593094 (opens the source filing in a new tab)

47. Trial

    PHASE3 registered

    Feb 5, 2020

    HER2-positive Early Breast Cancer · COMPLETED · sponsor: Hoffmann-La Roche · A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

    ClinicalTrials.gov · NCT04024462 (opens the source filing in a new tab)

48. Trial

    PHASE2/PHASE3 registered

    Jan 29, 2020

    Breast Cancer · ACTIVE_NOT_RECRUITING · sponsor: Hoffmann-La Roche · A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

    ClinicalTrials.gov · NCT04191499 (opens the source filing in a new tab)

49. Trial

    PHASE2 registered

    Jan 9, 2020

    Multiple Sclerosis · ACTIVE_NOT_RECRUITING · sponsor: Hoffmann-La Roche · A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis

    ClinicalTrials.gov · NCT04075266 (opens the source filing in a new tab)

50. Trial

    PHASE1/PHASE2 registered

    Aug 13, 2019

    Lymphoma, Non-Hodgkin · ACTIVE_NOT_RECRUITING · sponsor: Hoffmann-La Roche · A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

    ClinicalTrials.gov · NCT04077723 (opens the source filing in a new tab)

51. Trial

    PHASE1/PHASE2 registered

    May 23, 2019

    Diffuse Large B-cell Lymphoma · COMPLETED · sponsor: Hoffmann-La Roche · Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

    ClinicalTrials.gov · NCT03677154 (opens the source filing in a new tab)

52. Trial

    PHASE1 registered

    Dec 5, 2018

    Huntington's Disease · COMPLETED · sponsor: Hoffmann-La Roche · Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease

    ClinicalTrials.gov · NCT03664804 (opens the source filing in a new tab)

53. Trial

    PHASE1 registered

    Nov 7, 2018

    Schizophrenia · COMPLETED · sponsor: Hoffmann-La Roche · 18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia

    ClinicalTrials.gov · NCT06880328 (opens the source filing in a new tab)

54. Trial

    PHASE3 registered

    Apr 24, 2018

    Non-Small-Cell Lung · COMPLETED · sponsor: Hoffmann-La Roche · A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

    ClinicalTrials.gov · NCT03456063 (opens the source filing in a new tab)

55. Trial

    PHASE1 registered

    Mar 13, 2018

    B-Cell Lymphoma, Non-Hodgkin Lymphoma · COMPLETED · sponsor: Hoffmann-La Roche · A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

    ClinicalTrials.gov · NCT03467373 (opens the source filing in a new tab)

56. Trial

    PHASE3 registered

    Jul 5, 2017

    Neoplasms · COMPLETED · sponsor: Hoffmann-La Roche · A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

    ClinicalTrials.gov · NCT03194893 (opens the source filing in a new tab)

57. Trial

    PHASE2 registered

    Nov 19, 2015

    Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms, Lymphoma, Large-Cell, Anaplastic, Melanoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Primary Brain Tumors, Renal Cell Carcinoma, Sarcomas, Salivary Gland Cancers, Adult Solid Tumor · ACTIVE_NOT_RECRUITING · sponsor: Hoffmann-La Roche · Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

    ClinicalTrials.gov · NCT02568267 (opens the source filing in a new tab)

58. Trial

    PHASE3 registered

    Jun 7, 2014

    Asthma · COMPLETED · sponsor: Hoffmann-La Roche · A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate Asthma

    ClinicalTrials.gov · NCT02104674 (opens the source filing in a new tab)

59. Trial

    PHASE1 registered

    Nov 7, 2011

    Healthy Volunteer · COMPLETED · sponsor: Hoffmann-La Roche · A Single-Ascending-Dose Study of RO5469754 in Healthy Volunteers

    ClinicalTrials.gov · NCT01620931 (opens the source filing in a new tab)

60. Trial

    PHASE2 registered

    Jul 1, 2011

    Malignant Melanoma · COMPLETED · sponsor: Hoffmann-La Roche · A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases

    ClinicalTrials.gov · NCT01378975 (opens the source filing in a new tab)

61. Trial

    Study registered

    May 1, 2011

    Rheumatoid Arthritis · COMPLETED · sponsor: Hoffmann-La Roche · An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)

    ClinicalTrials.gov · NCT01394276 (opens the source filing in a new tab)